Management of proctitis in ulcerative colitis and the place of biological therapies.

Biological therapy clinical trial proctitis refractory therapy ulcerative colitis

Journal

Expert opinion on biological therapy
ISSN: 1744-7682
Titre abrégé: Expert Opin Biol Ther
Pays: England
ID NLM: 101125414

Informations de publication

Date de publication:
14 Jun 2024
Historique:
medline: 14 6 2024
pubmed: 14 6 2024
entrez: 14 6 2024
Statut: aheadofprint

Résumé

Approximately 20-30% of patients with ulcerative colitis (UC) may present with isolated proctitis. Ulcerative proctitis (UP) is a challenging condition to manage due to its significant burden in terms of disabling symptoms. PubMed was searched up to March 2024 to identify relevant studies on UP. A comprehensive summary and critical appraisal of the available data on UP is provided, highlighting emerging treatments and areas for future research. Patients with UP are often undertreated and the disease burden is often underestimated in clinical practice. Treat-to-target management algorithms can be applied to UP, aiming for clinical remission in the short term, and endoscopic remission and maintenance of remission in the long term. During their disease, approximately one third of UP patients require advanced therapies. Escalation to biologic therapy is required for refractory or steroid dependent UP. For optimal patient care and management of UP, it is necessary to include these patients in future randomized clinical trials.

Identifiants

pubmed: 38874980
doi: 10.1080/14712598.2024.2369189
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Diletta De Deo (D)

IBD Center, Humanitas Research Hospital - IRCCS, Rozzano, Milan, Italy.
Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.

Arianna Dal Buono (A)

IBD Center, Humanitas Research Hospital - IRCCS, Rozzano, Milan, Italy.

Roberto Gabbiadini (R)

IBD Center, Humanitas Research Hospital - IRCCS, Rozzano, Milan, Italy.

Paola Spaggiari (P)

Department of Pathology, Humanitas Research Hospital, Rozzano Milan, Italy.

Anita Busacca (A)

IBD Center, Humanitas Research Hospital - IRCCS, Rozzano, Milan, Italy.

Benedetta Masoni (B)

IBD Center, Humanitas Research Hospital - IRCCS, Rozzano, Milan, Italy.
Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.

Silvia Ferretti (S)

IBD Center, Humanitas Research Hospital - IRCCS, Rozzano, Milan, Italy.
Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.

Cristina Bezzio (C)

IBD Center, Humanitas Research Hospital - IRCCS, Rozzano, Milan, Italy.
Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.

Alessandro Armuzzi (A)

IBD Center, Humanitas Research Hospital - IRCCS, Rozzano, Milan, Italy.
Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.

Classifications MeSH